Cargando…

Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy

Background and objectives: To report the initial response to a single intravitreal brolucizumab (IVI-B) injection in wet age-related macular degeneration (wAMD) or polypoidal choroidopathy (PCV) complicated with either persistent subretinal fluid (SRF) or pigment epithelial detachment refractory to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Alan Y., Lin, Chih-Ying, Lin, Chun-Ju, Lai, Chun-Ting, Hsia, Ning-Yi, Lin, Jane-Ming, Tien, Peng-Tai, Meng, Ping-Ping, Ku, Wei-Ning, Chen, Wen-Lu, Tsai, Yi-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784980/ https://www.ncbi.nlm.nih.gov/pubmed/36556905 http://dx.doi.org/10.3390/medicina58121703

Ejemplares similares

Brolucizumab for macular degeneration
Publicado: (2020)

Polypoidal choroidopathy associated with choroidal nevus
por: Pascual-Camps, Isabel, et al.
Publicado: (2017)

Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study
por: Bilgic, Alper, et al.
Publicado: (2021)

Three-Month Results of Brolucizumab Intravitreal Therapy in Patients with Wet Age-Related Macular Degeneration
por: Michalska-Małecka, Katarzyna, et al.
Publicado: (2021)

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
por: Avaylon, Jaycob, et al.
Publicado: (2020)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Morphological Macular Changes Under Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration Refractory to Previous Anti-VEGF Treatment Compared with Treatment-Naive Eyes
por: William, Antony, et al.
Publicado: (2023)

Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy
por: Nam, Seung Wan, et al.
Publicado: (2022)

Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients
por: Gesualdo, Carlo, et al.
Publicado: (2023)

Bilateral blindness after uneventful brolucizumab injection for macular degeneration
por: Barchichat, Ilan, et al.
Publicado: (2022)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)
por: Van Cleemput, Liesbeth, et al.
Publicado: (2023)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
por: Abdin, Alaa Din, et al.
Publicado: (2022)

Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration
por: Yeom, Hoseok, et al.
Publicado: (2023)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi, Nicolas A, et al.
Publicado: (2019)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy
por: Matsumoto, Hidetaka, et al.
Publicado: (2021)

Genetic analysis of typical wet-type age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese population
por: Goto, Asako, et al.
Publicado: (2009)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
por: Maggio, Emilia, et al.
Publicado: (2022)

Intravitreal aflibercept combined with transpupillary thermotherapy in the treatment of refractory macular edema due to primary uveal melanoma
por: Huang, Yu-Te, et al.
Publicado: (2022)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
por: Garweg, Justus G., et al.
Publicado: (2023)

One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy
por: Ito, Arisa, et al.
Publicado: (2022)

Effect of Intravitreal Brolucizumab in the Treatment of Polypoidal Choroidal Vasculopathy With Foveal Lipid Exudation
por: Carta, Valentina, et al.
Publicado: (2023)

Serum Cholesterol Efflux Capacity in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Yanagi, Yasuo, et al.
Publicado: (2022)

Hypertension affects the treatment of wet age‐related macular degeneration
por: Wang, Ting, et al.
Publicado: (2021)

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
por: Bae, Ki Woong, et al.
Publicado: (2022)

Associations of 6p21.3 Region with Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Ye, Zimeng, et al.
Publicado: (2016)

Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience
por: Hsia, Ning-Yi, et al.
Publicado: (2021)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Age-related macular degeneration and premorbid allergic diseases: a population-based case–control study
por: Shen, Yi-Chen, et al.
Publicado: (2021)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2021)

Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy
por: Venkatesh, Pradeep, et al.
Publicado: (2015)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Genetic and Functional Dissection of ARMS2 in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Cheng, Yong, et al.
Publicado: (2013)

Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema After Dexamethasone Implants
por: Huang, Yu-Te, et al.
Publicado: (2022)

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
por: Ogura, Yuichiro, et al.
Publicado: (2022)

Changes of Estimated Glomerular Filtration Rate and Glycated Hemoglobin A1c in Diabetic Macular Edema Patients Treated by Ranibizumab and Aflibercept in the Tertiary Referral Hospital
por: Ku, Wei-Ning, et al.
Publicado: (2022)

Fractal analysis of polypoidal choroidal neovascularisation in age-related macular degeneration
por: Serra, Rita, et al.
Publicado: (2021)

Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections
por: Chang, Yen-Chieh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aoocsag52cslno42jm2m5bkb1e